skip to content

Market News

PureTech says two pharma funds invest in Akili

20 July 2016 07:36

PureTech Health notes an $11.9m expansion of its operating company Akili Interactive Labs' Series B financing - bringing the total Series B proceeds to $42.4m.

Amgen Ventures, the venture arm of Amgen, and Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (known as M Ventures in the United States and Canada) joined existing investors, including PureTech.

With the investments from Amgen Ventures and M Ventures, Akili now has four relationships with major biopharma companies or their investment affiliates, including its existing partnership with Pfizer, Inc. and an investment from Shire Pharmaceuticals.

Story provided by

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.